Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07553637 · ClinicalTrials.gov registry record · Phase 2
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
A Phase 2 study, sponsored by Alto Neuroscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
NCT07553637 is a Phase 2 study that is actively recruiting participants, run by Alto Neuroscience. The registered enrollment target is 178 participants.
The verdict
NCT07553637, a Phase 2 study, is actively recruiting participants, sponsored by Alto Neuroscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
Study Summary
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
Interventions
- DRUG Placebo
- DRUG ALTO-207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07553637
The ClinicalTrials.gov registry entry for NCT07553637 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alto Neuroscience, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07553637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07553637 about?
NCT07553637 is a clinical study titled "ALTO-207 in Adults With Treatment-resistant Depression (TRD)". The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
What is the current status of trial NCT07553637?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2026-05. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07553637?
The interventions under investigation include: Placebo (DRUG), ALTO-207 (DRUG).
Who is sponsoring clinical trial NCT07553637?
This trial is sponsored by Alto Neuroscience, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.